Dr Reddy's Buys Stugeron Brand from Johnson & Johnson

Hyderabad-based Dr Reddy's Laboratories said on Tuesday that it has finalized a definitive transaction the Stugeron brand from Johnson & Johnson across the EMEA countries, describing India and Vietnam as important growth markets for Stugeron.  

Stugeron is an antihistamine that contains the active ingredient cinnarizine and has been prescribed for the treatment of vestibular disturbances, including vertigo. The acquisition highlights Dr Reddy's continuing development in the anti-vertigo category, while also enhancing its growing Central Nervous System (CNS) portfolio.

According to MV Ramana, Chief Executive Officer of Branded Markets (India & Emerging Markets) for Dr Reddy's, this deal showcases the company's ongoing commitment to expanding its portfolio of therapeutic offerings.

Also Read: Designing Packaging Systems for Regulatory Compliance and Quality

Dr Reddy's plans to tap into its strong market access to expand the availability of the Stugeron brand into 18 important markets for the company in the broader Asia Pacific and EMEA regions including India and Vietnam. Ramana emphasized that this expansion is in alignment with Dr Reddy's overall business strategy of improving patient access and its ambitious goal of 1.5 billion patients by 2030.

Industry experts consider the purchase as a strategic move by Dr Reddy’s to increase its presence in the fast-growing anti-vertigo segment and re-establish its position in the CNS segment. With Stugeron’s established brand and Dr Reddy’s distribution channel, the purchase is anticipated to provide significant growth potential in both developed and emerging markets.